Development and validation of algorithms for identifying lines of therapy in multiple myeloma using real-world data

References

• National Comprehensive Cancer Network . NCCN Guidelines: Multiple Myeloma, Version 1.2024 (2023). www.nccn.org/guidelines/guidelines-detail?category=1&id=1445
   Google Scholar
• Kumar S . Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies. Hematology Am Soc Hematol Educ Program.2017(1), 518–524 (2017).
   PubMedGoogle Scholar
• Leow CC , LowMSY. Targeted Therapies for Multiple Myeloma. J Pers Med.11(5), 334 (2021).
   PubMed Web of Science ®Google Scholar
• Garfall AL . New Biological Therapies for Multiple Myeloma. Annu. Rev. Med. doi: 10.1146/annurev-med-050522-033815 (2023).
   PubMed Web of Science ®Google Scholar
• Kumar SK , CallanderNS , AdekolaKet al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 18(12), 1685–1717 (2020).
   PubMedGoogle Scholar
• Pereira MP , HoffmannV , WeisshaarEet al. Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. J Eur Acad Dermatol Venereol.34(10), 2373–2383 (2020).
   PubMed Web of Science ®Google Scholar
• Duma N , AzamT , RiazIB , Gonzalez-VelezM , AilawadhiS , GoR. Representation of Minorities and Elderly Patients in Multiple Myeloma Clinical Trials. Oncologist.23(9), 1076–1078 (2018).
   PubMed Web of Science ®Google Scholar
• Casey M , IslamM , ShoukierM , OdhiamboL , CortesJE. Are pivotal trials for drugs approved for leukemia, myelodysplastic syndromes, and multiple myeloma representative of the population demographics affected by these diseases?Blood138, 846 (2021).
   Web of Science ®Google Scholar
• Varma T , WallachJD , MillerJEet al. Reporting of Study Participant Demographic Characteristics and Demographic Representation in Premarketing and Postmarketing Studies of Novel Cancer Therapeutics. JAMA Netw Open.4(4), e217063 (2021).
   PubMed Web of Science ®Google Scholar
• Blonde L , KhuntiK , HarrisSB , MeizingerC , SkolnikNS. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician. Adv Ther.35(11), 1763–1774 (2018).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration . Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. Guidance for Industry. FDA-2021-D-1214 (14 January 2022). www.fda.gov/media/154714/download
   Google Scholar
• U.S. Food and Drug Administration . Real-World Data: Assessing Electronic Health Records and Medical Claims Data to Support Regulatory Decision-Making for Drug and Biological Products. Guidance for Industry. FDA-2020-D-2307 (14 January 2022). www.fda.gov/media/152503/download
   Google Scholar
• Rajkumar SV , HarousseauJL , DurieBet al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood117(18), 4691–4695 (2011).
   PubMed Web of Science ®Google Scholar
• Rajkumar SV , RichardsonP , SanMJF. Guidelines for determination of the number of prior lines of therapy in multiple myeloma. Blood126(7), 921–922 (2015).
   PubMed Web of Science ®Google Scholar
• Kumar SK , CallanderNS , HillengassJet al. National Comprehensive Cancer Network . NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020.J Natl Compr Canc Netw.17(10), 1154–1165 (2019).
   PubMed Web of Science ®Google Scholar
• International Myeloma Working Group . Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol.121(5), 749–757 (2003).
   PubMed Web of Science ®Google Scholar
• Davies F , RifkinR , CostelloCet al. Real-world comparative effectiveness of triplets containing bortezomib (B), carfilzomib (C), daratumumab (D), or ixazomib (I) in relapsed/refractory multiple myeloma (RRMM) in the US. Ann. Hematol.100(9), 2325–2337 (2021).
   PubMed Web of Science ®Google Scholar
• Chari A , RichardsonPG , RomanusDet al. Real-world outcomes and factors impacting treatment choice in relapsed and/or refractory multiple myeloma (RRMM): a comparison of VRd, KRd, and IRd. Expert Rev Hematol.13(4), 421–433 (2020).
   PubMed Web of Science ®Google Scholar
• Quan H , SundararajanV , HalfonPet al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med. Care43(11), 1130–1139 (2005).
   PubMed Web of Science ®Google Scholar
• Chubak J , PocobelliG , WeissNS. Tradeoffs between accuracy measures for electronic health care data algorithms. J. Clin. Epidemiol.65(3), 343–349 e342 (2012).
   PubMed Web of Science ®Google Scholar
• Jiao Y , DuP. Performance measures in evaluating machine learning based bioinformatics predictors for classifications. Quant Biol.4(4), 320–330 (2016).
   Google Scholar
• O’donnell JC , LeTK , DobrinRet al. Evolving use of real-world evidence in the regulatory process: a focus on immuno-oncology treatment and outcomes. Future Oncol.17(3), 333–347 (2021).
   PubMedGoogle Scholar
• Harricharan S , CurranE , LinHMet al. Real-world evidence in lung and hematologic oncology health technology appraisals: a review of six assessment agencies. Future Oncol.19(8), 603–616 (2023).
   PubMedGoogle Scholar
• Di Maio M , PerroneF , ConteP. Real-World Evidence in Oncology: Opportunities and Limitations. Oncologist.25(5), e746–e752 (2020).
   PubMed Web of Science ®Google Scholar
• Brown JS , MaroJC , NguyenM , BallR. Using and improving distributed data networks to generate actionable evidence: the case of real-world outcomes in the Food and Drug Administration’s Sentinel system. J. Am. Med. Inform. Assoc.27(5), 793–797 (2020).
   PubMed Web of Science ®Google Scholar
• Desai RJ , MathenyME , JohnsonKet al. Broadening the reach of the FDA Sentinel system: a roadmap for integrating electronic health record data in a causal analysis framework. NPJ Digit Med.4(1), 170 (2021).
   PubMed Web of Science ®Google Scholar
• Parikh R , ClancyZ , CandrilliS , ParikhK. Administrative data algorithms to identify diagnosis and treatment-related measures in patients with multiple myeloma: a validation study. Poster presented at the 2018 AMCP Managed Care & Specialty Pharmacy Annual Meeting. J Manag Care Pharm. 2018 Apr; 24(4-2):S29.Boston, MA (2018). April 25, 2018.
   Google Scholar
• La J , DumontierC , HassanHet al. Validation of algorithms to select patients with multiple myeloma and patients initiating myeloma treatment in the national Veterans Affairs Healthcare System. Pharmacoepidemiol Drug Saf.32(5), 558–566 (2023).
   PubMed Web of Science ®Google Scholar
• Nattinger AB , LaudPW , BajorunaiteR , SparapaniRA , FreemanJL. An algorithm for the use of Medicare claims data to identify women with incident breast cancer. Health Serv. Res.39(6 Pt 1), 1733–1749 (2004).
   PubMed Web of Science ®Google Scholar
• Nordstrom BL , WhyteJL , StolarM , MercaldiC , KallichJD. Identification of metastatic cancer in claims data. Pharmacoepidemiol Drug Saf.21(Suppl. 2), 21–28 (2012).
   PubMed Web of Science ®Google Scholar
• National Cancer Institute . Cancer Stat Facts: myeloma. https://seer.cancer.gov/statfacts/html/mulmy.html (29 March 2022).
   Google Scholar
• National Cancer Institute . Cancer Statistics Review 1975–2018: Table A.1 Number of Incidence Cases, 2014–2018 by Primary Cancer Site, Race and Sex (21 SEER Geographic Areas). https://seer.cancer.gov/csr/1975_2018/browse_csr.php (29 March 2022).
   Google Scholar
• U.S. Food and Drug Administration . FDA approves new therapy for patients with previously treated multiple myeloma. www.fda.gov/news-events/press-announcements/fda-approves-new-therapy-patients-previously-treated-multiple-myeloma (18 November 2021).
   Google Scholar
• U.S. Food and Drug Administration. FDA approves daratumumab for transplant-eligible multiple myeloma. www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-transplant-eligible-multiple-myeloma (3 February 2022).
   Google Scholar